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A human carboxypeptidase E/NF-α1 gene mutation in an
Alzheimer’s disease patient leads to dementia and depression
in mice
Y Cheng1,3, NX Cawley1,3, T Yanik2, SRK Murthy1, C Liu1, F Kasikci2, D Abebe1 and YP Loh1
Patients with Alzheimer’s disease (AD), a common dementia among the aging population, often also suffer from depression. This
comorbidity is poorly understood. Although most forms of AD are not genetically inherited, we have identified a new human
mutation in the carboxypeptidase E (CPE)/neurotrophic factor-α1 (NF-α1) gene from an AD patient that caused memory deficit and
depressive-like behavior in transgenic mice. This mutation consists of three adenosine inserts, introducing nine amino acids,
including two glutamines into the mutant protein, herein called CPE-QQ. Expression of CPE-QQ in Neuro2a cells demonstrated that
it was not secreted, but accumulated in the endoplasmic reticulum and was subsequently degraded by proteasomes. Expression of
CPE-QQ in rat hippocampal neurons resulted in cell death, through increased ER stress and decreased expression of pro-survival
protein, BCL-2. Transgenic mice expressing CPE-QQ did not show any difference in the processing enzyme activity of CPE compared
with wild-type mice. However, the transgenic mice exhibited poor memory, depressive-like behavior, severely decreased dendrites
in the hippocampal CA3 region and medial prefrontal cortex indicative of neurodegeneration, hyperphosphorylation of tau at
Ser396, and diminished neurogenesis in the dentate gyrus at 50 weeks old. All these pathologies are associated with AD and the
latter with depression and were observed in 50-week-old mice. Interestingly, the younger CPE-QQ mice (11 weeks old) did not show
deficits in dendrite outgrowth and neurogenesis. This study has uncovered a human CPE/NF-α1 gene mutation that could lead to
comorbidity of dementia and depression, emphasizing the importance of this gene in cognitive function.
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INTRODUCTION
Alzheimer’s disease (AD) is a common form of dementia among
the aging population and about 20–30% of AD patients also suffer
from depression.1 Depression is the most common neuropsychia-
tric disorder associated with AD2 and is present primarily in the
elderly.3 Studies have also shown an association between late-life
depression and AD.4 Whether depression is a risk factor for AD or
vice versa is unclear. Both AD and major depressive disorder
(MDD) share an overlapping pathophysiology. The pathology of
AD is typically characterized by: (1) the presence of neurofibrillary
tangles (NFTs) formed by aggregates of hyperphosphorylated tau,
a microtubule-associated protein in neurons,5 and (2) accumula-
tion of abnormal peptides (Aβ1–42) proteolytically cleaved from
β-amyloid precursor protein (APP), which form extracellular senile
plaques.6 These NFTs and plaques, found primarily in the
hippocampus and frontal cortex of the AD brain, trigger
neurodegeneration in these areas. Increased hippocampal plaques
and tangles have been found in AD patients that have a lifetime
history of depression. Serum Aβ1–40/42 ratio was also higher in AD
patients with depression.7 However, the etiology of the comor-
bidity of depression and cognitive/memory deficits in AD is not
well understood. Whether there might be certain forms of AD
arising from specific genetic mutations that predispose individuals
to both dementia and depression needs to be explored.
Most forms of AD are not genetically inherited. Only o0.3% of
AD cases are autosomal dominant familial AD (not sex-linked) and
the onset of the disease occurs early, before age 65.8,9 Autosomal
dominant familial AD is attributed to mutations in one of three
genes: APP, presenilins 1 and 2.10–12 Mutations in these genes
generally lead to an increase in the production of Aβ1–42, the
major component of senile plaques.13 More recently, high
throughput genetic analyses have identified many single nucleo-
tide polymorphisms (SNPs) associated with increased risk factors
for AD, rendering the possibility of a greater genetic contribution
to AD. Genome-wide association studies have identified some of
these genes as apolipoprotein E (APOE), TOMM40, and a
hypothetical gene LOC100129500 partially overlapping with APOE,
as well as a novel gene, EPC2.14 For the APOE gene, inheritance of
the ε4 allele increases the risk of AD by 3 times in heterozygotes
and 15 times in homozygotes.9 In addition, nine other genes with
AD risk SNPs (CLU, CR1, BINI1, ABCA7, MS4A, CD33, CD2AP, EPHA1
and TREM2) have been reported.15 Systematic meta-analyses of
AD genetic association studies have also identified many potential
AD susceptibility gene candidates.16 However, no studies have
demonstrated that any of these genes are associated with
depression.
In exploring the possibility of a genetic component for
comorbidity of dementia and depression in AD, we focused on
previous studies on the carboxypeptidase E (CPE)/neurotrophic
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factor-α1 (NF-α1) knockout mouse model, which showed both
severe neurodegeneration17 and depression.18 A search of various
databases uncovered a novel mutation in the CPE/(NF-α1) gene in
an expressed sequence tag (EST) reported by the Helix Research
Institute, Japan, obtained from the cortex of an AD patient.19 CPE,
first identified as a prohormone processing enzyme,20,21 is located
on chromosome 4 at 4q32.3 in the human genome.22 CPE is
expressed during early embryonic development in rats.23 It is
present in neurons and glial cells24 and has also been demon-
strated to be a neuroprotective protein.17,25 Knockout mice,
lacking CPE/NF-α1, exhibit obesity, infertility and type 2 diabetes,
reflective of the lack of or reduced levels of bioactive peptides.24,26
In addition, they exhibit severe neurodegeneration in the CA3
region of the hippocampus and have poor cognitive function,
including deficits in learning and memory.17 CPE/NF-α1 has been
shown to act extracellularly, through the ERK and Akt signaling
pathways to enhance expression of BCL-2, a pro-survival protein,
to mediate neuroprotection.27 These CPE/NF-α1 knockout mice
also showed diminished neurogenesis in the dentate gyrus of the
hippocampus and depressive-like behavior, which was rescued by
subcutaneous administration of FGF2, which induced
neurogenesis.18 Thus, the mutation in the CPE gene found in
the AD patient could potentially contribute to the histopathology,
memory deficits and depression associated with AD.
The CPE mutation found in the AD patient contains three
adenosine nucleotide insertions that result in the substitution of
amino acids after the pro-domain of the enzyme (Figure 1). The
mutation results in nine new amino acids replacing eight original
amino acids at the N terminus in the mutant protein compared
with the wild-type (WT) CPE. The new amino acids added contain
two adjacent glutamine (Q) residues; hence, we termed it a CPE-
QQ mutant. Interestingly, another analysis of polyA+ RNA pooled
from thalami of humans that died from brain trauma uncovered
an EST sequence with a similar mutation that resulted in a
predicted CPE protein sequence that contained the addition of
the same nine amino acids as the AD patient (Supplementary
Figure 1).
In the present study, we have characterized this CPE-QQ mutant
protein found in the AD patient, and examined the possibility that
it could give rise to the pathologies and behavioral deficits
characteristic of AD and depression. Indeed, we found that this
CPE-QQ mutant when expressed in hippocampal neurons led to
cell death, mediated by a mechanism involving endoplasmic
reticulum (ER) stress. Furthermore, transgenic mice expressing this
mutant exhibited memory deficits, depressive-like behavior,
neuronal degeneration, increased tau phosphorylation and
decreased neurogenesis in the hippocampus. Our findings
indicate that this human CPE mutation could result in neurode-
generation, memory deficits and depression linked to AD.
MATERIALS AND METHODS
Bioinformatic search for CPE gene mutation
A bioinformatic strategy was designed to find posttranscriptional
modifications in the CPE coding region, such as alternative splicing events.
Using CPE protein sequence (NCBI Reference Sequence: NP_001864), a
TBLASTN (search translated nucleotide databases using a protein query)
search was performed on non-redundant nucleotide sequence database.
Threshold were set to return maximum target hits, with an expected
threshold of ‘10’. Scoring parameters were set to ‘ BLOSUM62’ matrix with
a Gap costs of ‘Existence: 11 Extension:1’. Filters were set to avoid ‘Low
complexity regions’. Among several thousand hits, specific sequence
alignments were manually selected that have Gaps, positive amino acids or
split in the amino acid sequence alignment but still following the same
frame of the CPE open reading frame (ORF). Using this search strategy, we
identified an EST |DA134138.1| that had three adenosine inserts that
introduces nine amino acids at the N terminus of the CPE protein but still
maintaining the ORF. Owing to the presence of two glutamine residues in
the new sequence it was called CPE-QQ sequence. Following EST accession
# DA134138.1, we found that it was one of the collections of FLJ Human
cDNA Database (http://flj.lifesciencedb.jp/top/) and DA134138.1 was from
cortex RNA of a 65-year-old male AD patient sequenced for a high
throughput studies to identify alternative promoter regions of human
genes among normal and diseased patients.
Generation of the CPE-QQ construct and transgenic mouse
A construct containing the ORF of human CPE-QQ was custom synthesized
and cloned into the pcDNA3.1(+) expression vector with BamH1/Xho1
cloning sites (GenScript, Piscataway, NJ, USA). Sequence analysis confirmed
the insertion of three adenosine nucleotides consistent with the EST
database sequence of the mutant hCPE (Genbank ID# DA134138). The
pcDNA3.1 vector was digested with NruI/PvuII to generate a 2.44 kb
fragment containing the CMV enhancer and promoter, the CPE-QQ ORF
and the vector poly A site. This fragment was purified and used for
transgenic mouse production by Dr James Pickle (Transgenic Core Facility,
NIMH, NIH) on a C57/BL6 background. Founder animals were genotyped
with two sets of primers; QQ1 5′-CCGCGTTACATAACTTACGGTAAATGGC
C-3′, QQ2 5′-GGGTCTCCCTATAGTGAGTCGTATTAATTTCG-3′ that amplifies
the 5′-upstream sequence of the pcDNA3.1 vector only; and QQ4
5′-GCTTGCTCCTGAGACCAAGGCTG-3′, QQ6 5′-GCCTGCTATTGTCTTCCCAAT
CCTCC-3′ that amplifies the 3′-end of hCPE and the downstream pcDNA3.1
vector. Positive founders were mated with C57/BL6 WT mice to propagate
the lines, and F1 and subsequent generations were genotyped for the
transgene identification. All animal studies were done in accordance with
the NICHD Animal Care and Use Committee guidelines.
Cell biological analysis of Neuro2a and COS-7 cells expressing
CPE-QQ
Cells. Neuro2a cells (N2a), a mouse neuroblastoma cell line and
COS-7 cells, an African green monkey kidney cell line, were purchased
from ATCC (Manassas, VA, USA) and cultured at 37 °C under an atmosphere
of 5% CO2 in Dulbecco’s modified Eagles medium (DMEM) supplemented
with 10% fetal calf serum, 100 units ml− 1 penicillin, 100 μg ml− 1 strepto-
mycin and 4 mM glutamine. The cells were grown to ~ 70% confluency
and transiently transfected with CPE-WT, CPE-QQ, a mixture of both
constructs where noted or empty vector (EV) for 24 h using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol.
Enzymatic activity assays. COS-7 cells, transfected with CPE-WT or
CPE-QQ, as described above, were harvested in 50 mM sodium acetate,
pH 5.5, 0.01% Tx-100 and phenylmethylsulfonyl fluoride (1 mM), and frozen
and thawed once. The samples were centrifuged at 13 000 r.p.m. for
20 min in a microfuge and the supernatant saved. Aliquots were made and
frozen at − 80 °C until use. The COS-7 lysates containing ~ 100 ng protein
were incubated for 18 h at 37 °C in 50 mM sodium acetate, pH 5.5 with 5 μg
adrenocorticotropic hormone (ACTH) (1–17) peptide, with and without
cobalt (1 mM) and/or the CPE inhibitor, GEMSA (5 μM). The peptides were
separated by HPLC on a 4.6 × 250 mm 5 μm reverse phase Jupiter C18
column (Phenomenex, Torrance, CA, USA) and detected by absorbance at
214 nm. Buffer A was 0.1% TFA and buffer B was 80% acetonitrile/0.1% TFA
and the gradient was 30–40% B in 12 min. Western blot analysis confirmed
equivalent levels of CPE-WT and CPE-QQ protein in the cell extracts (data
not shown).
Secretion assays. For N2a cell secretion experiments, cells expressing CPE-
WT, CPE-QQ or both CPE-WT/CPE-QQ, were washed with DMEM and then
incubated with DMEM supplemented with 0.01% BSA for 5 h at 37 °C. The
media were collected and precipitated with 10% ice cold tri-chloroacetic
acid and the recovered proteins analyzed by western blot. The cells were
lysed with M-PER lysis buffer (Thermo Scientific, Waltham, MA, USA),
supplemented with 1 mM phenylmethylsulfonyl fluoride inhibitor. The cell
lysate was centrifuged at 13 000 g for 10 min at 4 °C and the supernatant
collected for analysis by western blot as follows. N2a cell lysate and 20 μl of
concentrated media were denatured, run on 4–20% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels and transferred onto
nitrocellulose membrane. The CPE-WT and CPE-QQ were detected using
mouse anti-CPE monoclonal antibody (1:5000, BD Biosciences, San Jose,
CA, USA) followed by IRDye conjugated secondary antibodies (Rockland
Immunochemicals, Gilbertsville, PA, USA) and analyzed with an Odyssey
Infrared Imager System and application software (LI-COR Biosciences,
Lincoln, NE, USA).
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Inhibitor studies. For inhibitor studies on the degradation of CPE-QQ and
CPE-WT, equivalent amounts of N2a cells were stably transfected with
human CPE-WT, CPE-QQ or EV (pcDNA3.1, negative control) cDNAs. Cells
were then treated with a proteasomal inhibitor, MG132 (5 μM, Sigma,
St Louis, MO, USA) or a lysosomal inhibitor, E64d (20 μM, Sigma), for 24 h
and then collected for western blot analysis. The cells were extracted with
M-PER lysis buffer, quantified by the Bradford Assay (Thermo Scientific) and
equal protein amounts were analyzed by western blot with a mouse anti-
CPE monoclonal antibody (1:10 000, R&D Systems, Minneapolis, MN, USA)
and then with a mouse anti-β-actin monoclonal (1:2000, Cell Signaling,
Danvers, MA, USA) antibody. The bands were visualized with luminal:
peroxide ECL substrate (Thermo Scientific). A Kodak X-Ray processor was
used for fixing and developing the signals on the X-ray films. The bands
were quantified by using Fuji (Image J) program (background subtracted).
In similar experiments, cell extracts were analyzed by western blot for
levels of CHOP, an ER stress-induced transcription factor.
Immunocytochemical analysis. N2a cells expressing CPE-WT and CPE-QQ
proteins were processed for immunocytochemistry (ICC) as previously
described28 and immunostained for CPE using mouse anti-CPE monoclonal
antibody (1:400, BD Biosciences) and rabbit anti-Calnexin (1:1000, Sigma).
Secondary antibodies were anti-mouse-Alexa488 and anti-rabbit Alexa568
at 1:1000 each (Thermo Fisher Scientific, formerly Molecular Probes). The
stained cells were visualized on a 510 Inverted META confocal microscope.
Cell biological analysis on primary neuronal cultures expressing
CPE-QQ
Cells. Hippocampal neuronal cultures were prepared as described
previously.27 The neurons were infected (multiplicity of infection 150)
with adenovirus expressing β-galactosidase (LacZ), CPE-WT or CPE-QQ
(Vector Biolabs, Malvern, PA, USA) for 96 h. After this time, various
experiments were performed to measure the effects of transduction.
For rescue experiments, the neurons were treated with recombinant
NF-α1/CPE (0.4 μM) or transduced with adenovirus expressing Bcl-2
(multiplicity of infection 20) for a further 96 h. In secretion experiments,
media from 1× 106 hippocampal neurons grown in 1 ml of culture medium
(Neurobasal+2% B27) were collected, centrifuged for 15 min at 12 000g to
remove cell debris and the supernatant analyzed by western blot.
WST-1 assay for cell viability. The viability of the cells was determined by
the WST-1 Cell Proliferation Reagent (Clontech, Mountain View, CA, USA)
assay in a 96 well plate according to the manufacturer’s protocol. Briefly,
after the different treatments, 10 μl of premixed WST-1 was added to each
well and the plate was maintained in a 37 °C incubator for 1–2 h. The
absorbance of the samples was then measured at 440 nm using a multi-
well plate reader.
Lactate dehydrogenase release assay for cell cytotoxicity. The cytotoxicity
of the cells after various treatments was evaluated by the extent of the
Figure 1. Nucleotide and amino acid sequence of human wild-type (WT) and Alzheimer’s disease (AD) mutant carboxypeptidase E (CPE). (a)
Inserted nucleotides in the mutant CPE sequence obtained from the human EST sequence of Alzheimer’s patient, DA134138.1 (RNA from
Invitrogen, Cat. #D6830-01) is shown in red. (b) Amino acid alignment of human WT-CPE and the mutant CPE, the inserted amino acids are
shown in red. The schematic diagram shows the linear domain, where the nine amino acids are introduced in the mutant protein. As a pair of
QQ amino acids is introduced, the mutant will be referred to as CPE-QQ. (c) X-ray crystal structure of the catalytic domain II of duck
carboxypeptidase D (CPD, Protein Data Bank ID #1qmu), a homologous protein to CPE. The QQ mutation occurs in the first β-sheet of CPD (see
arrow), which is associated in an anti-parallel manner with the β-sheet 2.
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release of lactate dehydrogenase. This was achieved with a CytoTox 96
Non-Radioactive Cytotoxicity Assay kit according to the manufacturer’s
instructions (Promega, Madison, WI, USA).
Western blotting. Protein lysates of hippocampal tissue and hippocampal
neurons in culture were prepared by homogenizing with T-protein
extraction reagent (T-PER, Thermo Scientific), supplemented with Com-
plete Inhibitor Cocktail (Roche, Indianapolis, IN, USA). The lysates were
collected, centrifuged at 13 000 g for 10 min at 4 °C and the protein
concentrations from supernatants determined. Twenty micrograms of
protein were denatured at 90 °C for 3 min and run on 4–20 or 12% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis gels and transferred
onto nitrocellulose membrane (Millipore, Billerica, MA, USA), according to
the standard protocol. After blocking with 5% nonfat milk at room
temperature for 1 h, CPE on the membrane was detected using a mouse
CPE monoclonal antibody directed against the 49–200 amino acid
sequence (BD Biosciences) at 1:5000. BCL-2 was detected using rabbit
anti-BCL-2 monoclonal antibody (Cell Signaling) at 1:2000. Phosphorylated
tau was detected by polyclonal rabbit anti-p-tauSer396 (1:3000, Santa Cruz,
Dallas, TX, USA) antibody. CCAAT-enhancer-binding protein homologous
protein (CHOP) was detected by monoclonal mouse anti-CHOP antibody at
1:3000 (Cell Signaling). Following primary antibody binding, the membrane
Figure 2. Carboxypeptidase E (CPE)-QQ transgenic mice exhibit memory deficits in Morris water maze test. (a, b) Bar graphs show no
difference in body weight (a) and fasting glucose levels (b) between wild-type (WT) and CPE-QQ mice. The values are the mean± s.e.m., t-test,
P40.05, n= 8. (c) Fifty-week-old CPE-QQ mice were subjected to the Morris water maze test. Graph shows the latency escape over 5 days. WT
and QQ mice exhibited a normal acquisition curve in the water maze task, suggesting that the transgenic mice had normal learning ability.
Two way ANOVA of genotype: F(1,113)= 1.627, P40.05. n value: WT= 12, CPE-QQ= 11. (d) Bar graphs show time spent by the mice in each
quadrant during probe test. WT mice spent almost twice as much time in the target quadrant, whereas QQ mice did not, indicating that the
transgenic mice have spatial memory deficits. (T: target quadrant, L: left quadrant, O: opposite quadrant, R: right quadrant.) t-test of target
quadrant: *Po0.05. n value: WT= 12, CPE-QQ= 11. (e) CPE-QQ mice spent more time immobile in the forced swim test than the WT mice,
indicative of depressive-like behavior. t-test, *Po0.05, n value: WT= 11, CPE-QQ= 13.
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was incubated with fluorescent conjugated anti-mouse or rabbit
antibodies (Amersham, Piscataway, NJ, USA) and visualized by the Odyssey
infrared imaging systems version 2.1 (LI-COR, Lincoln, NE, USA) and
bands were quantified by Odyssey software and expressed as arbitrary
units (AU). The CPE expression level for each sample was normalized with
β-actin and expressed as the mean± s.e.m. of AU from three separate
experiments.
Analysis of CPE-QQ transgenic mice
Immunohistochemistry. The brains of 50-week-old WT and CPE-QQ
transgenic mice were dissected from perfused mice and embedded in a
gelatin matrix using MultiBrain Technology (NeuroScience Associates,
Knoxville, TN, USA) or each brain was embedded and sectioned, all the
sections were coronal. The MultiBrain block was sectioned in the coronal
plane at 35 μm on an AO 860 sliding microtome. The sections were then
stained for doublecortin (DCX), p-tau, or MAP2 using polyclonal rabbit anti-
doublecortin (1:2000, Cell Signaling), polyclonal rabbit anti-p-tauSer396
(1:1000, Santa Cruz), and monoclonal mouse anti MAP2 antibody (1:3000,
Abcam, Cambridge, MA, USA), respectively, followed by Alexa Fluor 594
goat anti-rabbit secondary antibody (Invitrogen). After mounting of the
sections, images were taken from the hippocampus by a confocal
microscope (Zeiss LSM 510 Inverted Meta, Carl Zeiss Microscopy,
Thornwood, NY, USA) with × 20 or × 63 magnification. For counting of
DCX immunoreactive cells in the dentate gyrus, a fluorescent microscope
(Nikon eclipse 80i, Nikon Instruments, Melville, NY, USA) with a digital
camera was used (×20 objective).
Body weight and blood glucose measurements in transgenic mice. Fifty-
week-old WT and CPE-QQ transgenic mice were weighed at 0900 hours
and blood glucose was measured with a glucometer.
Behavioral studies. The Morris Water Maze was used to test spatial
learning and memory. Testing was performed in a circular pool, 1.2 m in
diameter, filled with water made opaque with the addition of nontoxic
white paint. Videotracking was achieved with the Anymaze software
(Stoerlting, Wood Dale, IL, USA) connected to a video camera and
navigational parameters were analyzed subsequently with the Anymaze
software. To measure the animals’ learning ability, a submerged platform
was placed in one quadrant of the pool. On day 0, the mice were allowed
to acclimatize in the apparatus as follows: the mouse was put on the
platform for 10 s, then let swim for 20–30 s, and then guided to the
platform for 10 s. On day 1, animals were placed into the pool, facing the
wall of the pool, in a new quadrant on each of the successive four trials
per day. The hidden platform remained in the same position for all these
trials. Mice were allowed a maximum of 90 s to locate the platform and
were left on the platform for 30 s before being removed. If the platform
was not reached in 90 s, the mouse was guided to the platform and
allowed to sit on it for 30 s. Escape latency was measured for five
consecutive days for the animals’ learning ability test. Twenty-four h after
the fifth day, a probe test was performed to measure the memory of the
animals. The hidden platform was removed from the pool, and the animals
were placed at the opposite quadrant where the hidden platform used to
be located. The mice were allowed to explore the pool for 90 s and the
activity of the mice was recorded and analyzed by the Anymaze software.
Animals were excluded from analysis if they did not search the platform to
escape.
The forced swim test was used to test for depressive-like behavior. The
forced swim test was conducted at 1300–1700 hour similarly to that
previously described.18 Briefly, the apparatus consisted of a 4-litre Pyrex
beaker (15 cm diameter) that contained 15 cm water (25 °C). Swimming/
immobility behavior was digitally recorded for 6 min and scored using the
Anymaze software. Immobility time is defined as the time that the animal
spent floating or engaged in minimal activity to keep afloat. WT and litter-
matched CPE-QQ mice 30–40 weeks of age were allowed to swim/
struggle/float for 6 min before being returned to the home cage. Fresh
water was used for each mouse. The data are presented as means and
standard errors of the mean.
Sucrose preference test was performed as previously described.18 Briefly,
the mice were habituated to the presence of two bottles containing sterile
water for 5 days. Following this acclimation, mice had the free choice of
either drinking the 1% sucrose solution or sterile water for a period of
4 days. Sucrose preference was calculated as a percentage of the volume
of sucrose intake over the total volume.
All animals were male and randomly selected for experiments at certain
ages in this study. The experimenter was blinded to the group allocation
during animal experiments, and was given the code by another
investigator to analyze the data after experiments.
Statistical analysis. Data were analyzed by student t-test or one-way
analysis of variance (ANOVA) followed by Tukey post-hoc multiple
comparisons tests where noted. Data are presented as means plus/minus
standard error of mean. Significance was set at Po0.05.
RESULTS
Bioinformatic analysis identifies CPE gene mutation in AD patient
A non-redundant nucleotide sequence database search with the
human CPE nucleotide sequence as queries (NM_001873.2 and
NM_013494.3, respectively) against the GeneBank EST database
identified an EST sequence entry from cortex RNA of a 65-year-old
male AD patient19 that had three adenosine inserts (for details
of bioinformatics methodology used, see ‘Materials and methods’
section, Figure 1a). This introduces nine new amino acids
in the mutant protein, replacing eight amino acids in CPE-WT
(Figure 1b) in the first beta-pleated sheet region after the pro-
domain of the CPE protein (Figure 1c), herein called CPE-QQ due
to the presence of two glutamine residues in the new sequence
(Figures 1b and c).
Transgenic mice expressing CPE-QQ exhibit memory deficits and
depressive-like behavior
To explore the biological function of the mutation, we made
transgenic mice expressing the CPE-QQ mutation. Although the
ratio of WT:QQ protein expressed could not be quantified due to
lack of a specific antibody to the CPE-QQ protein, mRNA
expression levels determined by RT-PCR showed CPE-QQ mRNA
expression was only found in the transgenic mice and there was
no difference in WT-CPE mRNA levels (Supplementary Figure S1).
We also examined body weight and fasting blood glucose levels in
the CPE-QQ mice as the CPE-knockout mice show these metabolic
changes.26 Figures 2a and b show that CPE-QQ mice did not
exhibit any difference in body weight and fasting blood glucose
levels compared with WT animals, respectively.
The animals were tested for their learning and memory deficits
using the Morris Water maze test. There were no differences in the
rate of acquisition of learning ability (Figure 2c) or swim speed
(Supplementary Figure S2) between the CPE-QQ and WT animals
at 50 weeks. The learning ability was also not different between
genotypes at 90 weeks (Supplementary Figure S3A) of age. Spatial
memory consolidation is recorded as the time the mouse spends
in each quadrant during the probe test following the escape
latency test. Both 50- (Figure 2d) and 90-week-old (Supplementary
Figure S3B) CPE-QQ mice spent less time in the target quadrant
compared with age-matched controls. In addition, we analyzed
the difference between the target quadrant and other quadrants
per strain in 50-week-old mice. In general, both CPE-QQ and WT
mice spent more time in the target quadrant compared with the
other quadrants; however a greater significant difference between
target quadrant and other quadrants were found in WT mice (For
WT mice: T vs L, Po0.001; T vs O, Po0.001; T vs R, Po0.001. For
CPE-QQ mice: T vs L, P= 0.008; T vs O, P= 0.048; T vs R, P= 0.02. t-
test). These results indicated that these CPE-QQ mice had deficits
in spatial memory.
We next tested for depressive-like behavior of the animals by
the forced swim test. CPE-QQ mice had a significantly increased
immobility time compared with WT mice in the forced swim test
(Figure 2e), indicating that the CPE-QQ mice had depressive-like
behavior. However, the CPE-QQ mice showed similar sucrose
preference as the WT mice (Supplementary Figure S4), this may be
due to the milder depression in CPE-QQ mice compared with CPE
KO mice.
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Transgenic CPE-QQ mice show decreased dendrites,
phosphorylated tau and decreased neurogenesis in the
hippocampus
To examine the histopathology of the CPE-QQ mouse brain, we
carried out immunohistochemistry on 50-week-old mice. Nissl
staining showed that there was no apparent neuronal loss in the
CPE-QQ mice compared with the WT mice in the hippocampus
(Supplementary Figure 5A). However, when the sections were
then stained with microtubule-associated protein 2 (MAP2), a
specific neuronal marker, the results show that there were much
Figure 3. Histopathology of carboxypeptidase E (CPE)-QQ mouse brain. (a) Confocal images ( ×63) showing much fewer dendrites indicating
neurodegeneration in CPE-QQ mice (50 weeks old) compared with the wild-type (WT) mice in CA3 region of hippocampus, in CPE-QQ mice.
(b) Confocal images (×63) showing phosphorylation of tau in DG of hippocampus in WT and QQ mice. (c, d) Western blot analysis of p-Tau
levels in hippocampus. Note that 50-week-old QQ mice had more tau phosphorylation in hippocampus than WT mice. t-test, n= 6, *Po0.05.
(e) Top panels: Confocal images (×20) and bottom panels of confocal images (×63) showed that 50-week-old QQ mice had less double cortin
staining in the dentate gyrus (DG) compared with WT mice, indicative of less neurogenesis in QQ mice. (f) Quantification of doublecortin
positive cells in DG. t-test, n= 4, *Po0.05. For all confocal images, scale bar: 50 μm. n value: WT= 4, CPE-QQ= 4.
Figure 4. Effects of carboxypeptidase E (CPE)-QQ mutation on its enzyme activity and on cell viability. (a) Untransfected COS-7 cells (i) or cells
expressing CPE-wild-type (WT) (ii) and CPE-QQ (iii) were extracted. The lysates were incubated for 18 h with ACTH(1–17) with and without
cobalt and/or GEMSA and the enzymatically processed products were analyzed by HPLC. Note that only CPE-WT generated the appropriate
peptide products (ACTH (1-16), ACTH (1-15) and ACTH (1-14) in a cobalt inducible and GEMSA inhibitable manner. (b) Western blot analysis of
the cell lysate and media from Neuro2a cells. Cells were transfected with CPE-WT (WT), CPE-QQ (QQ) or empty vector (EV). Note that there was
a decreased amount of CPE-QQ compared with WT in cells and none was secreted into the media, whereas the CPE-WT was (bottom panel).
Also, note that when CPE-QQ and WT were expressed together, there was a significant reduction of CPE-WT in the media (21.6± 6.8%
compared with WT alone (100%), n= 5). (c) Immunofluorescence confocal microscopy of Neuro2a cells expressing WT and CPE-QQ. Double
immunostaining of WT-CPE (left panel) or CPE-QQ (right panel) (green) with Calnexin (red) in Neuro2a cells. CPE-QQ is localized in the
perinuclear area and in a reticular distribution consistent with its localization in the endoplasmic reticulum (ER) in these cells. Note that cells
highly expressing the QQ CPE mutant appear to be more rounded indicative of unhealthy cells (insert). (d) Western blot of CHOP in Neuro2a
cells. Representative blot from two experiments are shown. Upper panel: cells were transfected with empty vector (EV), wild-type CPE (WT)
and the CPE mutant (QQ). Lower panel: CHOP levels increased in cells expressing CPE-QQ compared with WT. (e, f) Rescue of degradation of
CPE-QQ by proteosomal and lysosomal enzyme system inhibitors. Neuro2a cells were transfected with CPE-WT (WT), CPE-QQ (QQ) or EV, and
treated with and without MG132, a proteosomal inhibitor (e) or E64d (f), a lysosomal inhibitor. Representative blots of three experiments are
shown. Bar graphs show fold increase (%) of CPE protein, normalized against actin, in treated versus untreated cells expressing CPE-WT (WT),
CPE-QQ (QQ) and endogenous CPE-WT (EV). The values are the mean± s.e.m., one-way ANOVA analysis ((e) (MG132): F(2,9)= 147.9, Po0.001;
(f) (E64d): F(2,6)= 33.87, Po0.001), followed by Tukey test, *Po0.05 compared with the EV (control) group.
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fewer dendrites in the CA3 region and dentate gyrus of the
hippocampus of CPE-QQ mice compared with WT controls
(Figure 3a and Supplementary Figure 5B). Moreover, we also
found fewer dendrites in the prefrontal cortex of the CPE-QQ mice
(Supplementary Figure 5C). Our study showed that phosphoryla-
tion of tau using an antibody specific for Ser396, that is well
documented in AD cases,29 was significantly increased in the
dentate gyrus of the CPE-QQ mice compared with control mice
(Figures 3b–d). We also examined doublecortin staining, a marker
for immature neurons in the dentate gyrus of CPE-QQ mice. The
number of doublecortin positive cells present was significantly
decreased by ~ 50% compared with control WT mice, indicating
less neurogenesis in the mutant mice (Figures 3e and f). These
results taken together indicate that the CPE-QQ mice have many
of the histopathological characteristics of dementia, including AD,
as well as diminished neurogenesis characteristic of depression.
We also carried out immunohistochemistry on 11-week-old mice.
MAP2 staining showed a similar pattern of dendrite outgrowth in
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the dentate gyrus of the hippocampus of CPE-QQ mice compared
with WT mice (Supplementary Figure S6A); and doublecortin
staining suggested that the younger CPE-QQ mice did not have
obvious deficits in hippocampal neurogenesis (Supplementary
Figures S6B and C).
CPE-QQ protein lacks enzymatic activity, is not secreted and
induces ER stress in Neuro2a cells
Next, we investigated the cell biological mechanism underlying
how CPE-QQ could cause neurodegeneration using ex vivo
systems. The additional new amino acids in the mutant have a
calculated isoelectric point (pI) of 6.9, in contrast to the WT
sequence that has a pI of 8.8. This change in pI, would predict a
significant effect on the structure of the protein that may affect its
enzymatic activity. To investigate the enzymatic activity, plasmids
expressing CPE-QQ and CPE-WT, were transfected into COS-7 cells,
which normally do not express CPE, and soluble cell extracts were
made. Two preliminary analyses using ACTH(1–17) peptide as
substrate (see Figure 4a for sequence), were carried out to initially
demonstrate CPE activity in the WT and not the QQ expressing
cells. A third, more comprehensive analysis is described here.
Soluble cell extracts were incubated with ACTH(1–17), with and
without cobalt, which stimulates CPE enzymatic activity, and/or
the CPE inhibitor, GEMSA (Figure 4a). Lysates containing WT-CPE
generated peptide products: ACTH(1-16), (1-15) and (1-14)
representing sequential C-terminal cleavages of the basic residues
of the substrate, in a cobalt inducible and GEMSA inhibitable
manner (Figure 4a, middle panel). In contrast, lysates containing
CPE-QQ did not generate any cleavage products (Figure 4a, right
panel), similar to the control lysate from untransfected cells that
contain no CPE (Figure 4a, left panel). This result indicates that
CPE-QQ is enzymatically inactive.
To investigate if CPE-QQ is correctly trafficked in the cell, we
examined the secretion behavior of CPE-QQ from N2a cells, a
mouse neuroblastoma cell line, compared with CPE-WT. Western
blot analysis (Figure 4b) shows that although the CPE-QQ was
expressed (top panel), there was no secretion of the mutant in the
medium (bottom panel), compared with WT-CPE, which was
secreted. This observation suggests that CPE-QQ may not be
trafficked through the secretory pathway, but may be trapped in
the ER. Interestingly, when CPE-QQ was co-expressed with WT,
secretion of the WT was reduced to 21.6 ± 6.8% (± s.e.m., n= 5)
compared with cells expressing CPE-WT alone (right panel),
suggesting that WT-CPE might co-aggregate with CPE-QQ in the
ER, and is inhibited from traversing the secretory pathway.
To study the cellular localization of CPE-QQ in N2a cells, we
carried out ICC studies of N2a cells transfected with CPE-QQ or
CPE-WT. Figure 4c shows that CPE-QQ stains in the perinuclear
region of the cells and co-stained with Calnexin, an ER marker,
consistent with localization of the mutant in the ER (Figure 4c,
lower left and right panels). Moreover, many CPE-QQ cells appear
rounded (Figure 4c, lower panels, insert), indicating unhealthy
cells that might be undergoing ER stress, unlike the cells
expressing WT, which show staining in the cell body and neurites
(Figure 4c, upper panels). To determine if cells expressing CPE-QQ
are undergoing ER stress, we carried out western blot analysis
using the anti-CHOP antibody. The ER stress marker, CHOP, was
significantly elevated in N2a cells expressing CPE-QQ compared
with those expressing CPE-WT or EV control (Figure 4d, n= 2).
As the CPE-QQ protein appears to be accumulated in the ER
causing ER stress we examined the degradation systems that
might be responsible for degrading the mutant protein. Figure 4e
shows that the proteasome inhibitor, MG132, significantly
inhibited the degradation of CPE-QQ showing an approximately
eightfold higher accumulation of the protein in the cell on
treatment with the inhibitor. We then examined whether the cell
permeable lysosomal inhibitor, E64d (thiol protease inhibitor)
could inhibit the degradation of CPE-QQ. E64d treatment inhibited
degradation of CPE-QQ, showing a approximately twofold
increase in accumulation in the cell (Figure 4f). These results
suggest that degradation of CPE is primarily through the
proteosomal system, although some degradation may be
occurring through autophagy from the ER and final degradation
when autophagic bodies fuse with lysosomes.30
CPE-QQ causes cytotoxicity through ER stress in hippocampal
neurons
We investigated whether CPE-QQ could cause cytotoxicity in
hippocampal neurons. Figure 5a shows that expression of CPE-QQ
in rat hippocampal neurons resulted in reduced cell viability as
revealed by the WST assay. In addition, the lactate dehydrogenase
assay indicates that hippocampal neurons expressing CPE-QQ
show increased cytotoxicity compared with those expressing CPE-
WT (Figure 5b). Analysis of CHOP shows an increase in expression
in the neurons expressing CPE-QQ. This suggests that the decreased
viability of neurons expressing CPE-QQ compared with neurons
expressing CPE-WT (Figure 5c), is due to ER stress. Furthermore,
the pro-survival mitochondrial protein, BCL-2, in hippocampal
neurons expressing CPE-QQ, was decreased; indicating that the
mechanism of action of CPE-QQ involves decreased expression of
this protein, leading to apoptosis (Figure 5d). Overexpression of
BCL-2 in hippocampal neurons expressing CPE-QQ rescued cell
viability and cytotoxicity (Figures 5e and f).
WT-CPE rescues cell viability in hippocampal neurons expressing
CPE-QQ
We determined if exogenously applied purified WT-CPE protein
can rescue cell viability in hippocampal neurons expressing CPE-
QQ. First, we showed that the secretion of endogenous WT-CPE
from hippocampal neurons transduced with CPE-QQ was reduced
compared with neurons transduced with LacZ (Figure 6a and b).
Similar to that shown in Figure 5, the neurons transduced with
CPE-QQ showed decreased cell viability and increased cytotoxi-
city. We then added purified WT-CPE protein (400 nM) to the
medium to determine if that could rescue these defects. Figure 6c
and d shows that exogenous WT-CPE protein rescued cell viability
and cytotoxicity of the CPE-QQ neurons indicating that secreted
CPE has an important role in mediating neuroprotection.
DISCUSSION
AD is commonly associated with psychiatric comorbidities, the
most prevalent being depression.31 More than 50% of AD patients
develop depression one year after diagnosis of the disease.32
However, the etiologies of this comorbidity remain poorly
understood. A previous study has suggested a connection
between CPE with AD. It showed aberrant accumulation of CPE
in human AD plaques in different brain areas including the
neocortex and hippocampus. Furthermore, CPE was aberrantly
accumulated in degenerating neurites and activated astroglia of
human AD plaques. In addition, amyloid-forming transgenic mice
accurately recapitulate the aberrant CPE accumulation detected in
AD dystrophic neurites.33 In this study, we investigated whether a
novel mutation in the human CPE/NF-α1 gene (CPE-QQ) found in
an AD patient could lead to comorbidity of dementia and
depression. The likelihood that this mutation could cause memory
deficits and depression linked to AD is very high as CPE/NF-α1 has
been shown to have strong neuroprotective effects27 and
prevents depression during chronic stress.18 Indeed, our study
showed that transgenic mice overexpressing this CPE-QQ muta-
tion exhibited memory loss and depressive-like behavior. How-
ever, they showed apparent normal metabolic function as they
were not obese and had normal blood glucose levels, unlike the
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CPE/NF-α1 knock mouse26 and the CPEser202pro mutant mouse
(CPEfat/fat).24
The CPE-QQ mutation described here consists of three
adenosine inserts that results in the substitution of eight amino
acids in the CPE-WT protein for night new amino acids in the first
beta-pleated sheet after the pro-domain of the mutant CPE
protein (Figures 1b and c). Interestingly, an EST sequence from
pooled thalamic RNA of different humans (who died from brain
trauma) with two adenosine and one cytosine insertions was also
identified, that predicted the same core nine additional amino
acids as in CPE-QQ, added to the CPE/NF-α1 protein, in addition to
other amino acids upstream of this core (Supplementary
Figure S7). The existence of a similar CPE mutant protein in
humans suggests that the mutation is not unique to one
individual and that such a mutant protein might also give rise
to neurodegenerative disease and depression. In addition, the
recent description of the first human with a truncating
homozygous null mutation for CPE presenting with intellectual
disability,34 further supports the importance of the CPE protein in
cognitive function in humans. CPE-QQ-like mutations having the
predicted nine amino acid insertions may be rare as a search of
two human databases (1000 Genome and Esembl) have not
revealed such a mutation. However, other human CPE mutations
and SNPs exist, that could give rise to dementia and depression,
given the link between CPE/NF-α1 and cognitive function.
Our biochemical studies demonstrated that the human CPE-QQ
mutant protein is enzymatically inactive and therefore its role in
prohormone processing is eliminated. However, the transgenic
animals expressing this mutation did not show any weight gain or
difference in levels of fasting glucose from WT animals indicating
no apparent impairment of their metabolic functions. Unlike the
CPE-knockout mouse,26 there is probably sufficient WT-CPE
protein to perform the enzymatic prohormone processing
functions in the CPE-QQ transgenic animals that also express
CPE-WT. This is supported by our analysis that the levels of α-MSH
in the hypothalamus (a peptide requiring enzymatic activity of
CPE-WT to be generated) were unchanged in the transgenic mice
compared with WT mice (Supplementary Figure S8A). In addition,
our results also showed that the levels of orexin and GABA (which
could affect mood and memory) were unchanged in the
hypothalamus (Supplementary Figures S8B and C). We further
analyzed MAP2 expression as a potential essential gene to
determine if it could account for the observed phenotype as
some brain regions showed reduced dendrites in CPE-QQ mice.
Western blot analysis indicated that the total MAP2 expression did
not change in CPE-QQ mice in hippocampus and hypothalamus
(Supplementary Figures S8D and E), indicating that the loss of
dendrites is not due to a decrease in expression of an essential
gene such as MAP2.
We showed that the CPE-QQ mice exhibit memory deficits at 50
and 90 weeks of age, but with no impairment of spatial learning
ability even at 90 weeks of age. In addition, they showed mild
depressive-like behavior. Thus, these CPE-QQ mice exhibit
comorbidity of loss of cognitive function and depression-like
behavior. Analysis of the histopathology of the CPE-QQ mouse
brains revealed that the dendrites were greatly reduced, indicat-
ing neurodegeneration, in the CA3 region and dentate gyrus of
the hippocampus and the prefrontal cortex compared with WT
mice, areas of the brain involved in cognitive function and
depression.35,36 In addition, we have analyzed several other brain
regions including CA1 region of the hippocampus, parietal cortex
and hypothalamus. The results indicated that the dendrites in
these regions were normal in CPE-QQ mice (Supplementary
Figures S9A–C), suggesting that changes of dendrites in CPE-QQ
mice were restricted to certain regions in the brain. The CA3
region of the hippocampus normally expresses high levels of CPE
and has been shown in the CPE-knockout mouse to be highly
vulnerable to neurodegeneration during stress.37 Interestingly, we
Figure 5. Effect of overexpression of carboxypeptidase E (CPE)-QQ
on cellular function in hippocampal neurons. (a, b) Rat hippocampal
neurons were transduced with adenovirus carrying LacZ (control),
CPE-WT (WT) or CPE-QQ (QQ). Bar graphs show that CPE-QQ
reduced cell viability ((a) WST-1 assay) and increased cell cytotoxicity
((b) Lactate dehydrogenase (LDH) assay) compared with cells
expressing WT. One-way ANOVA analysis followed by Tukey test
for WST-1 assay: F(2,27)= 21.72, *Po0.05, n= 10. One-way ANOVA
analysis followed by Tukey test for LDH release assay: F(2,12)= 338.6,
*Po0.05, n= 5. (c) Western blots of CHOP expression in hippocam-
pal neurons expressing CPE-QQ and CPE-WT. Upper panel: blot
showing CPE-QQ (QQ) increased the expression of CHOP compared
with WT and LacZ. Lower panel: bar graphs showing quantification
of western blots above. One-way ANOVA analysis followed by Tukey
test: F(2,6)= 16.26, *Po0.05, n= 3. (d) Western blots of BCL-2
expression in hippocampal neurons expressing CPE-QQ and CPE-
WT. Upper panel: blot showing CPE-QQ (QQ) down regulated the
expression of BCL-2, an anti-apoptotic protein compared with WT
and LacZ. Lower panel: bar graphs showing quantification of
western blots above. One-way ANOVA analysis followed by Tukey
test: F(2,12)= 30.66, *Po0.05, n= 3. (e, f) Transduction of BCL-2 in
hippocampal neurons on cell viability and cytotoxicity. Bar graphs
showing that transduction of BCL-2 in neurons expressing CPE-QQ
(QQ) rescued the decreased cell viability (e) and increased
cytotoxicity (f). One-way ANOVA analysis followed by Tukey test
for WST-1 assay: F(2,12)= 127.6, *Po0.05, n= 5. One-way ANOVA
analysis followed by Tukey test for LDH release assay: F(2,12)= 79.5,
*Po0.05, n= 5.
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did not observe global loss of dendrites in the rest of the brain of
the CPE-QQ mice such as CA1 region of the hippocampus, parietal
cortex and hypothalamus (Supplementary Figures S9A–C). It is
possible that other brain regions are less dependent on CPE for
neuroprotection and sufficient protective effects may be provided
by the endogenous WT-CPE in the transgenic mice. The loss of
dendrites as observed in the CPE-QQ mice could lead to dementia,
as dystrophic neurites is a major neuropathological characteristic
of AD.38 Furthermore, dystrophic neurites have been found to be
associated with the early stage extracellular NFTs in another type
of dementia such as parkinsonism–dementia complex of Guam.39
Importantly, CPE-QQ mice showed abnormal hyperphosphoryla-
tion of tau at Ser396, which is specific for AD29 and phosphoryla-
tion of tau protein at sites Ser (396–404) is one of the earliest
events in AD.40 This hyperphosphorylation has been shown to
reduce affinity of microtubules, causing their destabilization and
degeneration of neurons.29 Besides neurodegeneration, accumu-
lating evidence indicates that altered adult neurogenesis have a
critical role in the progression of AD41 and depression.42 We
showed that these CPE-QQ mice have reduced neurogenesis in
the subgranular zone of the hippocampus, a phenotype similar to
the CPE-knockout mice, which exhibit severe depressive-like
behavior.18 Thus, the impaired memory and depressive-like
behavior in these CPE-QQ mice can be attributed to the
neurodegeneration and diminished neurogenesis in these mutant
mice, respectively. Altogether, this CPE mutation has a major
impact on the function of the central nervous system, producing a
pathological profile (Figures 2 and 3) in these CPE-QQ mice, with
many characteristics of AD or other dementia, as evidenced by
fewer dendrites in the hippocampus, memory deficits43 and
hyperphosphorylation of tau.44 The decreased neurogenesis in the
dentate gyrus likely accounts for the depressive phenotype in the
mutant mice.18,45,46 The observed deficits in the CPE-QQ mice
were unlikely to be caused by overexpression of CPE in abnormal
brain regions as ICC did not show aberrant localization or
excessive accumulation of CPE in the CPE-QQ mice compared
with WT mice in several brain regions examined (Supplementary
Figures S10A–D and Figures 11A–D). Moreover, western blot
analyses indicate that CPE protein was not excessively over-
expressed in the hippocampus (Supplementary Figure S10E), and
hypothalamus (Supplementary Figure 11E) or pituitary (Supple-
mentary Figure 11F) of CPE-QQ mice, although CPE-QQ mice did
show a small but significant increase in CPE expression in
hippocampus compared with WT mice. Interestingly, the deficits
of dendrite outgrowth and hippocampal neurogenesis were not
observed in younger CPE-QQ mice (11 week old), suggesting that
CPE-QQ mice were more vulnerable to neurodegeneration
during aging.
To understand the mechanism underlying the neurodegenera-
tive phenotype of the CPE-QQ mutation, we carried out cell
biological studies. CPE-QQ, when overexpressed in Neuro2a cells
or hippocampal neurons, resulted in poor viability. This was
attributed to the lack of trafficking of the mutant protein out of
the ER causing ER stress as evidenced by the increase in CHOP in
cells expressing the CPE-QQ mutation (Figures 4 and 5). In
addition, it was found that this mutant caused diminished
secretion of the endogenous WT-CPE protein (Figure 6a), suggest-
ing that the mutant protein likely aggregated with the endogen-
ous WT protein in the ER, preventing it from being trafficked
through the secretory pathway for secretion. The protease
inhibitor studies indicated that the accumulated mutant CPE
protein in the ER is primarily degraded in proteasomes as the
degradation was strongly inhibited by MG132; and possibly also
through autophagy from the ER and final degradation in
lysosomes as E64d, a lysosomal enzyme inhibitor, was effective
at inhibiting the degradation. Indeed, degradation of aberrant
proteins accumulated in the ER through both the proteosomal
pathway and autophagy is quite common.47 We further showed
that as a consequence of decreased secretion of CPE from
hippocampal neurons when transduced with CPE-QQ (Figures 4
and 6), there was also a decrease in the expression of the
mitochondria pro-survival (anti-apoptotic) protein, BCL-2. As it has
been reported previously that CPE/NF-α1 acts as a signaling
molecule to increase BCL-2 expression to protect neurons from
cell death induced by oxidative stress,27,48 insufficient CPE being
secreted from cells expressing CPE-QQ likely accounts for the
finding. Decreased neuronal cell viability in the CPE-QQ expressing
cells was rescued by expressing BCL-2 or addition of exogenous
CPE to the culture medium, indicating that diminished secreted
CPE levels and BCL-2 expression were responsible for the poor cell
viability of CPE-QQ neurons. Indeed, the poor neuronal viability
phenotype is likely due to a combination of decreased CPE-WT
activity, as we previously showed that CPE-knockout hippocampal
Figure 6. Carboxypeptidase E (CPE) rescues cell viability in CPE-QQ expressing neurons. (a, b) Rat hippocampal neurons were transduced with
CPE-QQ and secretion medium collected. Western blot (a) and quantification (b, bar graphs) show expression of CPE-QQ reduces
endogeneous CPE secretion. t-test, Po0.05, n= 4. (c, d) Bar graphs show that incubation of the hippocampal neurons expressing CPE-QQ with
400 nM recombinant CPE (rCPE) rescued both their decreased cell viability (c) and increased cytotoxicity (d). One-way ANOVA analysis
followed by Tukey test for WST-1 assay: F(2,12)= 16.37, *Po0.05, n= 5. One-way ANOVA analysis followed by Tukey test for lactate
dehydrogenase release assay: F(2,12)= 41.93, *Po0.05, n= 5.
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neurons had less viability,27 as well as a toxic gain of function of
CPE-QQ, which caused ER stress in the neurons.
In conclusion, cell biological studies indicate that the effect of
the CPE-QQ mutation is accumulation in the ER of WT and mutant
protein, resulting in ER stress and apoptosis of the neurons and
decreased secretion of WT-CPE required for neuroprotection. At
the physiological level, mice expressing CPE-QQ exhibit much
fewer dendrites indicative of neurodegeneration and hyperpho-
sphorylation of tau in the hippocampus and impaired memory, all
hallmarks of AD. In addition, these mice showed depressive-like
behavior likely due to diminished neurogenesis. Clearly, AD and
other dementia are complex diseases with various etiologies
involving genetic, epigenetic and environmental factors.49–51 The
human mutation of the CPE/NFα-1 gene uncovered in this study
has provided another unique potential genetic cause of AD that
can give rise to comorbidity of dementia and depression.
Moreover, this study reveals for the first time that humans with
CPE/NF-α1 mutations could potentially be predisposed to
dementia, as well as other cognitive function deficits.
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